Safety, Tolerability, and Antiviral Activity of GW695634G Monotherapy in HIV-1 Infected Adults

This study focuses on HIV-1 infected adults who have previously used a specific type of medication called Non-nucleoside reverse transcriptase inhibitor (NNRTI). The main goal is to explore the safety, tolerability, and antiviral effectiveness of a new drug, GW695634G. This research is important as it aims to find a new treatment option for HIV-1 infected individuals, potentially improving their care and quality of life. During this study, participants are randomly assigned to receive one of four different oral doses of GW695634G or a placebo for 10 days. The study measures the changes in HIV-1 levels, CD4+ cell count (a type of white blood cell that fights infection), and how the body processes the drug. The primary outcomes also include evaluating the safety and tolerability of the drug. The study takes place over multiple days, including Days 1 and 7.